Biosimilars are a relatively new drug category and major opportunity for savings in healthcare with estimates ranging from $44B and upwards. Biosimilars should also increase patient access through lower costs due to competition. Stakeholders need education about the safety and potential savings with biosimilars. A biosimilar is FDA- approved safe and effective medication that is compared to another medication – the original biologic and:
Biosimilars save employers and patients money.
The Acting Director of the Office of Therapeutic Biologics & Biosimilars at the Food and Drug Administration will present on the safety of biosimilars, and the President & CEO of the ERISA Industry Committee will present information about the savings with biosimilars.
Sara Yim, MD
Acting Director, Office of Therapeutic Biologics & Biosimilars
Food and Drug Administration
Sarah Yim, MD, is the Acting Director of the Office of Therapeutic Biologics and Biosimilars, in CDER’s Office of New Drugs (OND), within the FDA. Prior to that, she spent 2 years as Director of the Division of Clinical Review in the Office of Generic Drugs, and 11 years in various roles in rheumatology drug review in OND.
She received her undergraduate degree from Stanford University, her Doctor of Medicine degree from the Uniformed Services University of Health Sciences, and completed a postdoctoral fellowship in rheumatology at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), at the National Institutes of Health.
Annette Guarisco Fildes
President & CEO
The ERISA Industry Committee
Annette Guarisco Fildes is President and CEO of The ERISA Industry Committee (ERIC), leading the association’s public policy advocacy mission. ERIC is a national advocacy organization that exclusively represents large employers that provide health, retirement, paid leave, and other benefits to their nationwide workforces. With member companies that are leaders in every sector of the economy, ERIC advocates on the federal, state, and local levels for policies that promote flexibility and uniformity in the administration of their employee benefit plans.
Annette has a B.B.A. in Finance and a law degree from Hofstra University, as well as a Masters of Law in Taxation from Georgetown University Law Center.